12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MP4OX: Completed Phase IIb enrollment

Sangart completed enrollment of 348 patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 259 mL MP4OX.

Sangart Inc., San Diego, Calif.
Product: MP4OX (...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >